Patients with mosaic methylation patterns of the Prader-Willi/Angelman Syndrome critical region exhibit AS-like phenotypes with some PWS features by Umut Aypar et al.
RESEARCH Open Access
Patients with mosaic methylation patterns
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critical region exhibit AS-like phenotypes
with some PWS features
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Abstract
Background: Loss of expression of imprinted genes in the 15q11.2-q13 region is known to cause either Prader-Willi
syndrome (PWS) or Angelman syndrome (AS), depending on the parent of origin. In some patients (1 % in PWS
and 2–4 % in AS), the disease is due to aberrant imprinting or gene silencing, or both.
Results: We report here a 4-year-old boy on whom a chromosomal microarray (CMA) was performed due to mild
hand tremors, mild developmental delays, and clumsiness. CMA revealed absence of heterozygosity (AOH) spanning
the entire chromosome 15, suggesting uniparental isodisomy 15. The patient had no definitive phenotypic features of
PWS or AS. Methylation-sensitive multiplex ligation-dependent probe amplification (MS-MLPA) was performed to
determine the parent of origin of the uniparental disomy (UPD) by examining methylation status at maternally
imprinted sites. Interestingly, our patient had a mosaic methylation pattern. We identified nine additional previously
tested patients with a similar mosaic methylation pattern. CMA was performed on these individuals retrospectively to
test whether patients with mosaic methylation are more likely to have UPD of chromosome 15. Of the nine patients,
only one had regions of AOH on chromosome 15; however, this patient had numerous regions of AOH on multiple
chromosomes suggestive of consanguinity.
Conclusion: The patients with mosaic methylation had milder or atypical features of AS, and the majority also had
some features characteristic of PWS. We suggest that quantitative methylation analysis be performed for cases of
atypical PWS or AS. It is also important to follow up with methylation testing when whole-chromosome isodisomy is
detected.
Keywords: 15q11.2-q13, PWASCR, Chromosomal microarray, MS-MLPA, Mosaic methylation
Background
Prader-Willi syndrome (PWS) and Angelman syndrome
(AS) are distinct disorders caused by lack of expression
of paternally (PWS) or maternally (AS) imprinted genes
at 15q11–15q13, termed the Prader-Willi/Angelman
syndrome critical region (PWASCR). Approximately
99 % of PWS and 80 % of AS cases are caused by large
deletions, uniparental disomy (UPD) for chromosome
15, or imprinting center defects, respectively, while ap-
proximately 10 % of AS is due to point mutations in
UBE3A [1–3]. In some patients (1 % in PWS and 2–4 %
in AS), the disease is due to aberrant imprinting or gene
silencing, or both [4–7]. While these disorders are an
outcome of aberrations of the same region, the pheno-
types are strikingly different. PWS is characterized by
hypotonia, initial growth failure followed by obesity, hy-
perphagia, intellectual disability, developmental delay, and
hypogonadism [8]. AS is characterized by microcephaly,
severe intellectual disability, profound speech deficits, gait
ataxia, seizures, and happy disposition [3].
Despite these differences in phenotype, patients with a
combination of these features have been described. Some
of these patients were found to have a mosaic methylation
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pattern of the PWASCR. To further understand the
mechanism of pathogenesis and phenotype of patients
with mosaic methylation pattern, we studied 10 patients
with mosaic methylation pattern tested between June
2007 and June 2013 at the Mayo Clinic Clinical Molecular
Genetics and Clinical Cytogenetics laboratories.
Results
To date, we have identified 10 cases with mosaic methy-
lation pattern of the PWASCR tested at the Mayo Clinic
Clinical Molecular Genetics and Cytogenetics laboratories
(Table 1). The specimens were all from younger patients,
ranging from 2 to 11 years old, and both sexes were
equally represented (6 males, 5 females). Figure 1a and 1b
show representative normal copy number and mosaic
methylation pattern, respectively, of the PWASCR as de-
tected by MS-MLPA (case 1). All of the cases except cases
1 and 2 had normal copy number and heterozygosity of
chromosome 15 as detected by CMA. Cases 1 and 2 had
normal copy number of chromosome 15; however, ab-
sence of heterozygosity (AOH) was identified. AOH span-
ning the entire chromosome 15, suggesting uniparental
isodisomy 15, was observed for case 1 (Fig. 2a), and case 2
had regions of AOH on chromosome 15; however, this
case had numerous regions of AOH on multiple chromo-
somes, suggesting consanguinity.
Case 1 was a 4-year-old boy with mild developmental
delays, mild hand tremors, and clumsiness (ataxia). Re-
sults of fragile X testing were negative. CMA identified
nonmosaic AOH spanning the entire chromosome 15,
suggestive of uniparental isodisomy 15 (Fig. 2a). The pa-
tient had no phenotypic features definitively suggestive
of PWS or AS. MS-MLPA was performed to determine
the parent of origin of the UPD by examining methyla-
tion status at maternally imprinted sites. When com-
pared to normal controls, in the absence of a deletion,
patients with AS are expected to have maternally
imprinted sites with no methylation (plotting to zero),
while patients with PWS are expected to have sites with 2
methylated copies (ratio of 2). Interestingly, our patient had
a ratio of ~0.3 (Fig. 1b). After the test results were received,
additional clinical information was obtained, which showed
that the patient was much less severely affected than ex-
pected for AS. While he had features similar to those of
AS, such as essential tremors and clumsiness (ataxia), he
had no seizures, dysmorphic features, or obesity.
We then identified nine additional previously tested
patients with a similar mosaic methylation pattern.
CMA was performed to test whether patients with mo-
saic methylation are more likely to have UPD of
chromosome 15. Of the nine patients, only one (case 2)
had regions of nonmosaic AOH on chromosome 15;
however, this patient had numerous regions of AOH on
multiple chromosomes suggestive of consanguinity. Case
2 was an 11-year-old girl with developmental delay,
speech delay, and hypotonia. She also had normal results
of chromosome, PWAS fluorescence in situ hybridization
(FISH), and UPD studies.
The remaining eight cases had no abnormalities of
chromosome 15 or any other pathogenic copy number
variations. Case 3 was a 3-year-old boy who had an atyp-
ical or milder AS phenotype, including speech delay with
apraxia, global developmental delay, mild hypotonia,
microcephaly (head circumference at second percentile),
and abnormal electroencephalogram showing nocturnal
seizures. The patient was also born with congenital heart
disease, but there were no other health concerns (weight
at 96th percentile, height at 94th percentile). Results of
laboratory tests, including chromosomes, fragile X, UPD,
and UBE3A sequencing, were all normal. At about age
7 years, the patient was also noted to have mild to mod-
erate intellectual disability, attention-deficit/hyperactivity
disorder, behavioral issues, sleep-related problems, and
extremely reduced motor coordination (ataxia).
Case 4 was a 6-year-old girl with a happy disposition,
developmental delay, hypotonia, and speech delay with
apraxia. However, she progressed well cognitively and
performed on track with peers academically. There were
no other health concerns, and results of laboratory tests,
including metabolic, mitochondrial DNA, and muscle
biopsy, were normal.
Case 5 was a 6-year-old girl who had milder features
of AS. She had a happy demeanor, developmental delay,
intellectual disability, seizures, macrocephaly, and
diabetes.
Case 6 was a 6-year-old boy who was obese partly due
to his constant obsession to hide, hoard, and sneak food
(hyperphagia). The patient had developmental delay,
speech delay (nonverbal), autism, and temper/aggression
issues but no seizures. He did not have an obvious
movement disorder but received physical and occupa-
tional therapy earlier in life. Results of chromosome,
PWAS FISH, and fragile X tests were all normal.
Case 7 was a 2-year-old girl with developmental delay,
mild hypertonia, reflux, and weight loss due to pancre-
atic insufficiency.
Case 10 was a 10-year-old boy who was initially
thought to have PWS because of his moderate intellec-
tual disability, developmental delay, skin picking, and hy-
perphagia. However, he also had AS features, including
microcephaly (head circumference at 25th percentile),
absent speech, excitability, happy demeanor, ataxic gait,
insomnia, abnormal eye movement, strabismus, umbilical
hernia, and pectus excavatum. At age 12, he had failure to
thrive (weight at 10th percentile), short stature (height at
50th percentile), and early puberty.
For cases 8 and 9, no clinical information was
available.
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Discussion
Although PWS and AS are caused by lack of paternal or
maternal, respectively, expression of imprinted genes at
the same region (PWASCR), they are phenotypically dis-
tinct disorders. PWS is characterized by hypotonia, initial
growth failure followed by obesity, hypogonadism, and
variable degrees of intellectual disability. Typical features
of classic AS are severe intellectual disability, profound
language deficits, gait ataxia, seizures, microcephaly, and
happy demeanor. In contrast to these distinct features,
Fig. 1 Results of Methylation-Sensitive Multiplex Ligation-Dependent Probe Amplification in Cases With Mosaic Methylation Pattern of the Prader-Willi/
Angelman Syndrome Critical Region. Copy number peak ratios are determined by comparing patients with normal controls (2 copies/2 copies = 1.0),
in this case no deletion is observed (a). The methylation probes are designed to hybridize to maternally imprinted loci; therefore, when compared to
normal controls, in the absence of a deletion, patients with Angelman syndrome are expected to have no methylation (plotting to zero), while patients
with Prader-Willi syndrome should have 2 methylated copies (ratio of 2). Interestingly, our patient (case 1) had a ratio slightly below 0.5 on average (b)
Fig. 2 Results of Chromosomal Microarray in Case 1. Smooth signal is plotted at 2, indicating that two copies of the chromosome 15q arm are
present without any deletion or duplication of the Prader-Willi/Angelman syndrome critical region. Allele peaks show the genotype calls. Genotype calls
and allele dosage normalization are performed as follows: the formula for allele peaks is A – B, where A is the signal of the A allele and B is the signal of
the B allele. The allele peaks are normalized such that AA = 1, AB = 0, and BB =−1. Therefore, the absence of heterozygosity would be observed as loss of
the AB allele peaks (plotted at 0) with only AA (plotted at 1) and BB (plotted at −1) allele peaks present, as shown with case 1
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patients with a combination of these phenotypes have
been described in the literature.
In 1999, Gillessen-Kaesbach et al. reported seven atyp-
ical AS patients with obesity, hypotonia, and intellectual
disability who were initially thought to have PWS [9].
These patients also lacked ataxia, microcephaly, and AS
facial features, and three of the seven had active speech.
However, their methylation pattern was suggestive of
AS. At least five of these seven patients had a weak mater-
nal band indicative of mosaicism. Buiting et al. described
six additional patients with atypical AS, but also ten
patients with typical symptoms of AS who had a mosaic
methylation pattern [5]. Their study found that the pa-
tients with methylation mosaicism had a broad clinical
spectrum that ranged from typical AS, through mild AS,
to atypical AS. Methylation mosaicism was rare in their
patients with PWS; however, two of the patients with
PWS also showed mosaicism. Their study concluded that
the epimutations of the maternal chromosome are often
mosaic. Nazlican et al. reported 24 patients with mosaic
imprinting defects and also concluded that these patients
can have milder or atypical AS [10]. In their study, pa-
tients with milder AS had a higher percentage of normal
cells; however, patients with the same ratio of normal and
imprinting defect cells did express different phenotypes.
In contrast, Wey et al. described a patient with mosaic im-
printing defect who had relatively high levels of normally
methylated cells, and yet this patient had an almost typical
phenotypic expression of PWS [11]. This highlights the
difficulty in assigning severity and the spectrum of pheno-
typic expression on the basis of the ratio of normal and
abnormal cells. Lawson-Yuen et al. reported two cases
with atypical AS, one of whom had a mosaic methylation
pattern [12]. They concluded that the diagnosis of AS
should not be ruled out in patients with milder presen-
tations, such as those with some language development
and normocephaly. Camprubi et al. identified two pa-
tients with AS who had mosaic methylation patterns
and, interestingly, one of these patients displayed a mild
AS phenotype while the other displayed a PWS-like
phenotype [13].
The phenotypes associated with mosaic methylation
pattern of the PWASCR in our patient cohort are in
accordance with those previously reported. All of the pa-
tients had mosaic methylation pattern of the maternally
imprinted genes, suggesting a diagnosis of AS spectrum.
While all the patients had milder or atypical features of
AS (Table 1), the majority (5 of 8 cases with clinical
information) had some features characteristic of PWS,
such as hypotonia (cases 2, 3, and 4), hyperphagia (cases
6 and 10), and obesity (case 6). Of note, most of the
cases had limited clinical information available; there-
fore, the presence of PWS-like features in the remainder
of patients cannot be ruled out.
The mechanism of pathogenesis for case 1 is especially
interesting. There are several reports of mosaic UPD as
a consequence of trisomy 15 rescue that resulted in
PWS [14–16], and recently, Izumi et al. reported 2 cases
with mosaic UPD that resulted in mosaic methylation
pattern of the PWASCR [17]. In addition, patients with
AOH on 15q11.2 have been described with features
including developmental delay, intellectual disability,
autism, epilepsy, feeding difficulty, and other features
[18]. However, these cases are unlike case 1 presented in
this study. For case 1, the UPD detected by CMA is not
mosaic, while the methylation pattern detected by MS-
MLPA is mosaic for the maternally imprinted genes.
Also, the patients with mosaic UPD tend to have a clas-
sic PWS phenotype, while our case 1 has atypical AS.
Conclusions
On the basis of our data, we conclude that patients with
mosaic methylation pattern of the maternally imprinted
genes tend to have milder or atypical AS and the major-
ity have features that resemble PWS. We recommend that
quantitative methylation analysis be performed for cases
of atypical PWS or AS. It is also important to follow up
with methylation testing when whole-chromosome isodis-
omy is detected. However, the mechanism behind methy-
lation mosaicism remains unclear.
Methods
Cases
Case 1 was initially detected by chromosomal microarray
(CMA) performed at the Mayo Clinic Clinical Cytogen-
etics Laboratory, and methylation-sensitive multiplex
ligation-dependent probe amplification (MS-MLPA;
MRC-Holland) was performed subsequently. After case
1 was identified, an additional 9 cases with similar mo-
saic methylation pattern of the PWASCR as detected by
MS-MLPA were identified through the results database
of the Mayo Clinic Clinical Molecular Genetics Laboratory.
In these 9 cases, CMA was performed as part of this study.
For almost all the cases, limited phenotypic information
was available because the only sources were the reason for
ordering the test and any information provided by the
ordering physician by phone when testing was done.
DNA extraction and MS-MLPA
Genomic DNA extraction was performed using the Gen-
tra Puregene method (Qiagen) on total blood leukocytes.
MS-MLPA was performed using Salsa MS-MLPA Kit
ME028 (MRC-Holland). Briefly, 200 ng of genomic
DNA was denatured at 98 °C for 10 min. Probes were
then hybridized at 60 °C for 16 to 24 h. On completion,
each reaction was divided into 2 tubes of equal volume;
the ligation reaction alone was performed in 1 tube
while ligation and simultaneous digestion with HhaI
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were performed in the second, both at 49 °C for 30 min.
Each reaction then underwent polymerase chain reaction
amplification using universal primers according to the
manufacturer’s protocol. On completion, 8.5 μL Hi-Di
Formamide (Life Technologies) and 0.5 μL GeneScan
500 ROX Size Standard (Life Technologies) were added
to 1 μL of each reaction. This mixture was denatured at
95 °C for 5 min and placed on an ice-water slurry for an
additional 5 min. Samples were then subjected to capillary
electrophoresis on an ABI 3100 (Applied Biosystems).
MS-MLPA results were analyzed using GeneMarker ver-
sion 1.8 (SoftGenetics, LLC) to determine copy number
and methylation status of the PWASCR [19]. The fluores-
cent signals from the copy number probes are com-
pared to normal controls. The methylation probes are
designed to interrogate maternally imprinted loci (ma-
ternal allele methylated). Therefore, when compared to
normal controls, the ratio of methylated probes will in-
crease accordingly in the presence of additional copies of
the maternal allele but not because of the presence of add-
itional paternal alleles. When compared to normal con-
trols, in the absence of a deletion, patients with AS are
expected to have maternally imprinted sites with no
methylation (plotting to zero), while patients with PWS are
expected to have sites with 2 methylated copies (ratio of 2).
Chromosomal microarray
CMA was performed using CytoScan HD (Affymetrix)
according to the manufacturer’s protocol. Data were ana-
lyzed using Chromosome Analysis Suite (ChAS) software
(Affymetrix).
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